European Industry Demands Action To Sustain Health Systems
COVID Pandemic ‘A Wake-Up Call That Revealed Clear Weakness’
Industry actors and outsiders alike discussed existing challenges for the EU healthcare system amid significant economic pressures, while calling for action to ensure a workable system for low-priced medicines.
You may also be interested in...
Why Did Novartis/1A Pharma Withdraw Its Paracetamol Liquid From The German Market?
HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.
Sandoz: EU Stakeholders Must Stand Up For Proper Competition Behavior
Sandoz and Teva were among representatives discussing intellectual property and other legal challenges during the first day of Medicines for Europe’s 2022 annual conference. The European Commission’s Directorate-General for Competition director, Paul Csiszár, added his insight on legal issues.
Using Digital Tools To Unpick The Adherence Problem
An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.